Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Relay Therapeutics Inc (NASDAQ:RLAY) stands against the other ...

For instance, in the second-largest M&A deal announced so far this year, Eli Lilly has acquired Scorpion Therapeutics for $2.5bn. The deal is focused on Scorpion’s pipeline of precision cancer drugs, ...

Glick, Ph.D., who has been with the firm since its inception in 2021 and was previously founder of IFM Therapeutics and Scorpion Therapeutics ... Foresite Capital, Logos Opportunities Fund ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

Plymouth drugmaker IDRx was bought by GSK plc (NYSE: GSK) for $1 billion upfront, while Eli Lilly and Co. paid Boston-based Scorpion Therapeutics Inc. up to $2.5 billion for its lead cancer drug.

Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor ...

In a significant move to bolster its pipeline and capabilities, Relay recently acquired Scorpion Therapeutics in a $2.5 billion cash transaction. This acquisition is viewed by analysts as a ...